The goal of this activity is to improve the knowledge, competence and performance of learners to integrate new and emerging therapies into treatment for HER2-positive breast cancer treatment.
This program is intended for global medical oncologists and other healthcare providers who care for patients with breast cancer.
- Integrate recent practice-changing advances in the treatment of HER2-positive MBC
- Identify new and emerging therapies for third line and beyond for HER2-positive MBC
- Assess clinical trial results for novel HER2-directed and targeted therapies in this setting
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.